European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

James M. Foran, Ama Z.S. Rohatiner, David Cunningham, Razvan A. Popescu, Philippe Solal-Celigny, Michele Ghielmini, Bertrand Coiffier, Peter W.M. Johnson, Christian Gisselbrecht, Felix Reyes, John A. Radford, Eric M. Bessell, Bertrand Souleau, Aziz Benzohra, T. Andrew Lister

Research output: Contribution to journal › Article › peer-review

406 Scopus citations

Fingerprint

Dive into the research topics of 'European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences